Mia's Feed
Medical News & Research

Innovative Stem Cell Technique Accelerates Creation of Microglia for Brain Research and Disease Modeling

Innovative Stem Cell Technique Accelerates Creation of Microglia for Brain Research and Disease Modeling

Share this article

Harvard researchers have developed a swift and efficient method to generate human microglia-like cells from stem cells, enabling advanced neurodegenerative disease research and therapeutic development.

2 min read

A groundbreaking approach at Harvard University has enabled the rapid and efficient generation of human microglia-like cells from induced pluripotent stem cells (iPSCs). Microglia, vital immune cells in the brain accounting for about 10% of its cells, play essential roles in neuroinflammation, clearing debris, and supporting neural circuits. Dysfunction of microglia is linked to various neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's disease, ALS, and multiple sclerosis.

Traditionally, obtaining human microglia is challenging due to the invasive biopsies required, and rodent microglia differ significantly from humans, complicating translational research. To overcome these hurdles, researchers at the Wyss Institute and Harvard Medical School led by George Church developed a novel system that reduces the differentiation process from 35 days to just four, saving time and resources.

This new method builds on the TFome™ platform, a comprehensive library of transcription factors (TFs) critical to cell fate determination. The team engineered TF libraries specific to microglia and screened different combinations to identify a potent six-TF cocktail capable of transforming iPSCs into microglia-like cells rapidly. These cells exhibited key genetic and functional similarities to primary human microglia, including responses to inflammatory stimuli and disease-related proteins like TDP-43.

Further refinement involved additional screening with a second set of TFs, resulting in a 6-TF cocktail that enhances microglia maturity and functionality. The cells demonstrated expected behavior when exposed to neuroinflammatory signals, such as interferon gamma, and pathogenic proteins associated with neurodegeneration, confirming their potential use in studying disease mechanisms.

The ability to produce microglia efficiently opens new avenues for brain disease research, drug discovery, and personalized medicine. This platform technology also holds promise for generating other difficult-to-isolate cell types, advancing the development of next-generation regenerative therapies. Overall, this innovation represents a significant step toward better understanding and treating neurological diseases.

Source: https://medicalxpress.com/news/2025-06-stem-cell-platform-aims-recreate.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Post-Pandemic Increase in Head and Shoulder Injuries Among Youth Hockey Players Revealed by National Data

A recent study highlights a significant rise in head and shoulder injuries among youth hockey players post-pandemic, emphasizing the need for improved safety measures and protective equipment to prevent severe trauma.

Influence of Sociodemographic Factors and Treatment Timing on Amblyopia Outcomes

Early detection and treatment adherence, influenced by sociodemographic factors, are vital for successful amblyopia management and reducing health disparities among children.

Using Wastewater Surveillance to Detect Cancer-Linked HPV Strains

Uruguayan researchers are utilizing wastewater analysis to monitor high-risk HPV genotypes linked to cervical cancer, offering a promising tool for disease surveillance and prevention efforts in resource-limited settings.

Supporting Vaping Cessation: Strategies for Those Quitting Nicotine Vapes

Learn about effective strategies and support systems to help individuals quit nicotine vaping, addressing the rising demand for cessation assistance in New Zealand and beyond.